Retreatment of patients with the same chemotherapy: Implications for clinical mechanisms of drug resistance

Annals of Oncology

Volumn 12, Issue 1, 2001, Pages 23-27

  Cara, S ^a   Tannock, I F ^b  

^a CENTRE LÉON BÉRARD   (France)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Cancer chemotherapy; Drug resistance; Retreatment; Review

Indexed keywords

ALTRETAMINE; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; MELPHALAN; METHOTREXATE; MITOLACTOL; PACLITAXEL; PREDNISONE; PROCARBAZINE; TIOGUANINE; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; BREAST CANCER; CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DOSE RESPONSE; DRUG RESISTANCE; HAIRY CELL LEUKEMIA; HODGKIN DISEASE; HUMAN; LUNG SMALL CELL CANCER; MEDICAL INFORMATION; MULTIPLE MYELOMA; OVARY CANCER; PRIORITY JOURNAL; PUBLICATION; RETREATMENT; RETROSPECTIVE STUDY; REVIEW; TIME; UROGENITAL TRACT CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS;

EID: 0035138459     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008389706725     Document Type: Review

References (38)

1. P-glycoprotein, multidrug resistance and tumor progression
2. Multidrug resistance: Molecular mechanisms and clinical relevance
3. Drug resistance and experimental chemotherapy
4. Clinical drug resistance: The role of factors other than P-glycoprotein
5. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
6. Multidrug resistance: Clinical relevance in solid tumors and strategies for circumvention
7. Aspects of cytotoxic drug penetration, with particular reference to anthracyclines
8. Distribution and activity of antineoplastic drugs in a tumor model
9. Conventional cancer therapy: Promise broken or promise delayed?
10. Penetration of anticancer drugs through solid tissue: A factor that limits the effectiveness of chemotherapy for solid tumors
11. Heterogeneity and phenotypic instability of chemotherapeutic and immunologic sensitivity in murine and human, melanoma cell clones
12. Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents
13. Reinduction chemotherapy for acute nonlymphocytic leukemia
14. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: A proposal based on the results of retreatment by thioguanine, cytosine arabinoside and daunorubicin (TAD 9) in 150 standardized first-line therapy
15. Retreatment with 2-CdA of progressed HCL patients
16. Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: No acquired resistance
17. Unmantained remissions in multiple myeloma
18. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse
19. Reinduction with the same cytostatic treatment in patients with metastatic breast cancer: An Eastern Cooperative Oncology Group study
20. Chemotherapy for small-cell lung cancer: Induction and reinduction with VOCA
21. Retreatment with the induction regimen in small-cell lung cancer relapsing after an initial response to short term chemotherapy
22. Reinduction chemotherapy in small-cell lung cancer
23. Treatment of relapse of small-cell lung cancer in selected patients with the initial combination chemotherapy carboplatin, etoposide and epirubicin
24. Paclitaxel retreatment in patients with platinum and paclitaxel resistant ovarian cancer
25. Recurrent ovarian carcinoma: Retreatment utilizing combination chemotherapy including cisdiamminedichloroplatinum in patients previously responding to this agent
26. Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer
27. Second-line M-VAC therapy in patients previously treated with the M-VAC regimen for metastatic urothelial cancer
28. Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group
29. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy
30. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens
31. Lung cancer
32. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
33. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: A randomized study
34. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group
35. Importance of dose and dose intensity in the treatment of small-cell lung cancer
36. Progress in chemotherapy for metastatic breast cancer
37. Adjuvant CMF in breast cancer: Comparative 5-year results of 12 versus 6 cycles
38. The effect of increasing dose intensity and cumulative dose of adjuvant cyclophosphamide in node positive breast cancer. Results of NSABP B-25